pSivida Limited Completes Recruitment of European Pancreatic Cancer Study and Releases Preliminary Findings

BOSTON & PERTH, Australia--(BUSINESS WIRE)--pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced the completion of the recruitment stage of the Phase IIa clinical study of BrachySilTM for the treatment of inoperable pancreatic cancer at three leading hospitals in the United Kingdom and Singapore. All are major centers for cancer therapy.
MORE ON THIS TOPIC